Home
overview

SMi have produced a unique conference which deals exclusively with the crucial issues surrounding the field of osteoporosis treatment and prevention.

Life expectancy is constantly increasing and the number of elderly people continues to rise in relation to young people. At the same time the number of patients affected by osteoporosis is growing steadily. The pharmaceutical market for osteoporosis is likely to more than double by 2006. This conference will bring you up to date with the latest advances and issues surrounding osteoporosis. Both treatment and prevention of osteoporosis will be addressed. Additionally the latest approaches to diagnostic tools will be presented.

An outstanding panel of speakers will deliver vital information. The conference will combine the experience of some of the pharmaceutical key players in the osteoporosis field with the experience of the biotechnology sector. Indeed this conference is your vital first step to incorporating all the most recent developments in osteoporosis. This unique conference will show how your organisation can effectively optimise its own resources to improve its future growth potential through an efficient drug development process.

Conference programme

8:30 Registration and Coffee

9:00 Chairman’s Opening Remarks

Dr Tim Clay

Dr Tim Clay, Healthcare Research Manager, Frost and Sullivan

9:10 OSTEOPOROSIS: MAGNITUDE OF THE PROBLEM

Dr Philip J de Vane

Dr Philip J de Vane, Vice President, Clinical Affairs and North American Medical Director, Wyeth-Ayerst Laboratories

  • Direct national expenditure for treating osteoporosis and its consequences
  • Growing numbers of osteoporosis patients
  • Increased awareness of the disease
  • Improvements in techniques for early diagnosis
  • Preventing bone injuries due to osteoporosis
  • 9:40 ELI LILLY: THE TREATMENT AND PREVENTION OF OSTEOPOROSIS

    Dr Tim Garnett

    Dr Tim Garnett, European Clinical Development Physician, Eli Lilly

  • Developing a new compound for the treatment of osteoporosis
  • Bringing a SERM to the market
  • Clinical profile of evista
  • Benefits for the patient
  • Pharmacoeconomic implications of a successful osteoporosis product
  • 10:20 ORGANON: TISSUE-SPECIFIC TREATMENT FOR THE PREVENTION OF OSTEOPOROSIS

    Prof Herjan J T Coelingh Bennink

    Prof Herjan J T Coelingh Bennink, Programme Director, Reproductive Medicine, Organon

  • Combining the advantages of estrogen without their known disadvantages
  • Livial’s tissue specific activity
  • Advantages of Livial
  • Increasing patient’s compliance
  • Pharmacoeconomical implications of Livial
  • Successfully receiving marketing approval for Livial
  • 11:00 Morning Coffee

    11:20 RHONE-POULENC RORER: MEETING THE PATIENTS NEEDS

    Dr Marie-Paule Dain

    Dr Marie-Paule Dain, Associate Director, Endocrinology, Rhône-Poulenc Rorer

  • Estalis ™ , a new combination estrogen/progestin patch for HRT
  • Advantages of Estalis ™
  • Choosing the optimal drug delivery system
  • Benefit for the patient
  • 12:00 SIGNAL PHARMACEUTICALS: FROM TARGET DISCOVERY TO LEAD DEVELOPMENT

    Dr John K Westwick

    Dr John K Westwick, Project Manager, Signal Pharmaceuticals

  • A new class of small molecules termed selective estrogen receptor modulators (SERM)
  • Mimicking the positive effects of estrogens by inhibiting bone loss in postmenopausal women
  • Combining the bone protective effects of estrogens with a potentially improved safety profile
  • Line extension through anti-estrogenic effects
  • Bone formation remains a challenge for new osteoporosis therapies
  • Targets within the BMP signalling pathway may provide opportunities to develop small molecule bone anabolic agents for the future.
  • 12:40 Lunch

    13:40 SUCCESSFUL MARKETING STRATEGIES

    Tim Bradley

    Tim Bradley, Business Team Head, Rheumatology/HRT, Novartis

  • Managing a broad bone and HRT portfolio
  • Key strategic marketing issues
  • Strategic responses
  • Key factors driving growth in HRT / osteoporosis
  • 14:20 JOINING FORCES TO DEVELOP AND MARKET NEW DRUGS

    Ketil Bjarnason

    Ketil Bjarnason, International Clinical Project Manager, Novo Nordisk

  • Meeting the needs in a highly demanding market
  • Benefits of co-developing and co-promoting new products
  • Selecting the right partner
  • Finding a mutuallly beneficial agreement
  • Structuring the collaboration
  • 15:00 CONTRIBUTIONS TO THE AREA OF OSTEOPOROSIS

    Dr Brian H Vickery

    Dr Brian H Vickery, Director, Musculoskeletal Research, Inflammatory Diseases Unit, Roche Bioscience

  • Focusing on the prevention and treatment of osteoporotic fracture
  • Recent studies with an injectable biphosphonate
  • Identification of a new tissue selective vitamin D receptor modulator
  • Sequential use of anabolic and antiresorptive therapy
  • Coordinating diagnosis and therapeutics
  • Benefits of Integrated Health Care Solutions for the patient
  • 15:40 Afternoon Tea

    16:00 RESEARCH ON THERAPIES FOR OSTEOPOROSIS

    Dr Edward F Nemeth

    Dr Edward F Nemeth, Vice President, Chief Scientific Officer, NPS Pharmaceuticals

  • Exploring ways to halt and reverse the progression of osteoporosis
  • Using their proprietary technology related to calcium receptors
  • Calcilytics: compounds that act as antagonists at the calcium receptor on parathyroid cells
  • Triggering the release of the body’s own storage of PTH to stimulate bone growth
  • Creating a distinct advantage in cost and ease of use over injections of PTH or chemical analogues of PTH
  • Working with SmithKline Beecham
  • 16:30 INVOLVING THE IL-1 RECEPTOR AND THE TNF RECEPTOR FAMILY MEMBER, RANK, INTO THE TREATMENT OF OSTEOPOROSIS

    Dr Bill Dougall

    Dr Bill Dougall, Staff Scientist, Molecular Biology, Immunex

  • Involvement of Interleukin-1 receptor in osteoporosis
  • Mechanism of action of Il-1 receptor
  • Identification of the novel TNF receptor member RANK and its cognate ligand (RANK-ligand)
  • The pivotal role of RANK-ligand in osteoclastogenesis
  • Mechanism of action of the receptor RANK
  • 17:00 Chairman’s Closing Remarks and Close of Day One

    8:30 Re-registration and Coffee

    9:00 Chairman’s Opening Remarks

    Dr Juliet Compston

    Dr Juliet Compston, Lecturer in Medicine and Honorary Consultant Physician, University of Cambridge

    9:10 AXYS: TRANSFORMING GENE DISCOVERIES INTO DRUGS

    Dr James T Palmer

    Dr James T Palmer, Project Team and Group Leader, Cathepsin K Programme, Axys Pharmaceuticals

  • Cathepsin K, a cysteine protease target
  • Involvement of cathepsin K in osteoporosis
  • Developing small molecule inhibitors of cathepsin K as a treatment for osteoporosis
  • Solving the three-dimensional crystal structure of cathepsin K
  • Benefits of research collaborations with world-class pharmaceutical companies
  • Choosing the right partner
  • 9:40 FOCUSING ON THE DISCOVERY OF GENES

    Dr Laurence Faure

    Dr Laurence Faure, Director, Medical Research and Genomic Resources, Genset

  • Contributing to high-resolution genetic mapping
  • Using its proprietary technologies and integrated genomics platform
  • Maximising the pace and medical relevance of its genomics discoveries for complex traits
  • Providing pharmaceutical companies with patented genomics information
  • Entering into focused strategic partnerships
  • Assisting pharmaceutical companies throughout the drug life cycle
  • 10:20 DISCOVERY AND DEVELOPMENT OF SMALL MOLECULE DRUGS IN OSTEOPOROSIS

    Dr Andrés Negro-Vilar

    Dr Andrés Negro-Vilar, Senior Vice President Research and Chief Scientific Officer, Ligand Pharmaceuticals

  • Addressing major unmet patients needs in osteoporosis
  • Applying gene transcription technology
  • Using intracellular receptors (IR) technology
  • Addressing osteoporosis in both males and females
  • Enhancing therapeutic and safety profiles
  • Developing a global pharmaceutical business
  • 11:00 Morning Coffee

    11:20 GENETIC APPROACH TO DEVELOP NOVEL TREATMENTS FOR OSTEOPOROSIS

    Dr Mark Osborne

    Dr Mark Osborne, Osteoporosis Project Leader, Genome Therapeutics

  • Progress in identifying a gene associated with high bone mass
  • Using a unique family resource to gain understanding of the biology associated with the high bone mass gene
  • Using their proprietary high-throughput physical mapping, DNA sequencing and gene discovery technologies
  • Confirming the identity and biology of the high bone mass gene by functional studies
  • Jointly filing patent applications
  • Pharmaceutical partnerships to advance the gene discovery programme commercially
  • 12:00 GEMINI HOLDINGS: FROM GENES TO DRUGS

    Dr Paul Kelly

    Dr Paul Kelly, Chief Executive, Clinical Director, Gemini Holdings

  • Building a resource of human clinical data and associated DNA samples
  • Working on the discovery of genetic factors involved in osteoporosis
  • Providing a research and development discovery programme
  • Identification of diagnostic probes
  • Finding original targets for small molecule pharmaceutical research
  • Tailored therapy in osteoporosis, a platform that includes genetics, proteomics and clinical epidemiology
  • 12:40 Lunch

    14:00 AIMING AT A MECHANISTICALLY NOVEL TREATMENT FOR OSTEOPOROSIS

    Dr Robert Jackson

    Dr Robert Jackson, Executive Director, R and D, Chiroscience

  • The need for a therapy that can significantly increase bone density
  • Sclerosteosis: a human mutation that causes large increases in bone density
  • The concept of mutation as a surrogate for drug action
  • Mapping the sclerosteosis gene
  • Strategy for developing a new class of drugs to treat osteoporosis
  • 14:40 PROVIDING QUANTITATIVE MEASURE OF HUMAN BONE RESORPTION

    Thomas A Bologna

    Thomas A Bologna, President and CEO, Ostex International

  • Discovery and commercialisation of products associated with osteoporosis
  • Quantitative bone resorption measurement
  • Predicting skeletal response to hormonal antiresorptive therapy
  • Therapeutic monitoring
  • Pharmacoeconomical implications of successfully monitoring bone resorption
  • Securing their market position
  • 15:20 Afternoon Tea

    15:40 RISK ASSESSMENT AND MONITORING OSTEOPOROSIS PREVENTION AND TREATMENT

    John Coombes

    John Coombes, Vice President, Marketing and Sales, Metra Biosystems

  • Bone mass measurement at the point of care - measuring the STATE of bone health
  • QUS-2 ™ - fully portable, dry, scanning, quantitative calcaneal ultrasonometer
  • Biochemical markers of bone turnover - measuring the RATE of bone destruction and its reversal
  • Pyrilinks®-D and Alkphase-B® - urine and serum immunoassays for improving risk assessment and monitoring drug treatment
  • Enabling informed physician and patient decisions about osteoporosis prevention and treatment
  • 16:20 PROVIDING A RAPID POINT-OF-CARE DIAGNOSTIC TEST

    John Curtis

    John Curtis, Managing Director, Cortecs Diagnostics

  • Correlation of biochemical markers with bone resorption
  • Correlation of high bone resorption with osteoporosis and an increased risk of fracture
  • Developing a rapid test system for quantifying bone resorption
  • Mechanism of action of Osteosal ™
  • Benefits for the patient
  • Pharmacoeconomical aspects of providing rapid point-of-care diagnostic tests
  • 17:00 Chairman’s Closing Remarks and Close of Conference

    +

    Workshops

    Managing Clinical Trials: Improving and Speeding the Process
    Workshop

    Managing Clinical Trials: Improving and Speeding the Process

    Stakis St Ermins Hotel
    28th June 1999
    London, United Kingdom

    Stakis St Ermins Hotel

    Caxton Steet
    London SW1H 0QW
    United Kingdom

    Stakis St Ermins Hotel

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SMi GROUP LTD

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
    Registered in England No: 3779287 VAT No: GB 976 2951 71




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.